Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Kukoamine B Mesilate in Healthy Volunteers
NCT02219971Phase 1Completed
- Sponsor
- Tianjin Chase Sun Pharmaceutical
- Start
- Aug 2014
- Primary completion
- May 2015
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of kukoamine B in sepsis (7 arms), sponsored by Tianjin Chase Sun Pharmaceutical. Primary endpoint: Incidence of adverse events at 7 days. Started Aug 2014; status: completed.
02
Drugs
kukoamine B
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT02219971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219971.